About US
Contact us
-
Roche negotiating for rest of Chugai for $10BA year ago, CEO Schwan said there was no need to buy the 40% it didn't own Just last month Roche CEO Severin Schwan indicated he wasn't interested in mega-deals to build his company, only smaller, mo2014/8/22
-
2014 PhexTour （Pharma Excipients Technical Application National Tour Seminar) 5nd station--Changchun2014 PhexTour （Pharma Excipients Technical Application National Tour Seminar) 5nd station--Changchun, was successfully concluded on August 7 at Jindu Hotel . More than 90 technical persons from 20 ph2014/8/21
-
2014 PhexTour （Pharma Excipients Technical Application National Tour Seminar) 4nd station--Tonghua2014 PhexTour （Pharma Excipients Technical Application National Tour Seminar) 4nd station--Tonghua, was successfully concluded on August 5 at East Holiday Hotel . More than 90 technical persons from2014/8/20
-
Docs to FDA: Biosimilars should have different names than branded drugsEver since theFDAdrafted a set of rules forbiosimilarsin 2012, a debate has been raging over whether those drugs should carry the same generic names as the products they emulate. Now, some doctors are2014/8/19
-
Biogen ready to steal market share with newly minted MS drug PlegridyBiogen Idec ($BIIB) has added another bow to itsmultiple sclerosisquiver. With the FDA's approval of Plegridy, a long-acting form of its popular Avonex, Biogen can fight for an even bigger share of th2014/8/19
-
Roche's Avastin nabs quick FDA nod for cervical cancer useAfter promising last month to fast track its review of Roche's ($RHHBY) Avastin in cervical cancer, the FDA has come back with a positive verdict--a full two months before its deadline. The agency app2014/8/18
-
Pfizer, Merck, pick up hefty vax sales bump with CDC nod in seniorsPfizer's ($PFE)Prevnar 13, the world's best-selling vaccine, scored a big win Wednesday, nabbing a CDC committee nod for universal use in adults over the age of 65. And once payer coverage kicks in, t2014/8/18
-
Sanofi introduces authorised generic version of EloxatinSanofi US has introduced an authorised generic version of Eloxatin (oxaliplatin injection), a platinum-based drug used in combination with infusional 5-fluorouracil / leucovorin. Launched through San2014/8/15
-
US FDA grants orphan drug designation to Mirati’s mocetinostat for DLBCLUS-based pharmaceutical company Mirati Therapeutics has received orphan drug designation from the US Food and Drug Administration (FDA) for its mocetinostat for diffuse large B-cell lymphoma (DLBCL).2014/8/15
-
New era about to dawn: Novartis, and now Celltrion, present biosimilars to the FDABiosimilarshold huge promise, with estimates for this decade running from $35 billion to $200 billion and growing exponentially from there. And of course the U.S., being the world's largest pharma mar2014/8/14